About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

379188 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 07/24/2021.
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Our Science

marizomib (Proteasome Inhibitor)

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

 

Proposed Mechanism of Action

Marizomib is a proteasome inhibitor derived from a novel marine-obligate actinomycete that belongs to the ?-lactone-?-lactam superfamily of proteasome inhibitors.1?In in vitro experiments, marizomib has demonstrated irreversible binding to and inhibition of all 3 proteolytic subunits of the human proteasome complex, resulting in inhibition of proteasome activity.2,3

Celgene acquired this asset from Triphase in 2016. Triphase continues to support marizomib?s development by remaining involved with the ongoing clinical trials.